DUBLIN, Dec. 21, 2021 /PRNewswire/ — The “Global Immunology Partnering 2014-2021: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.
Global Immunology Partnering 2014 to 2021 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
-
Trends in Immunology partnering deals
-
Financial deal terms for headline, upfront and royalty by stage of development
-
Immunology partnering agreement structure
-
Immunology partnering contract documents
-
Top Immunology deals by value
-
Most active Immunology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.
The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report Scope
Global Immunology Partnering 2014 to 2021 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.
Global Immunology Partnering 2014 to 2021 includes:
-
Trends in Immunology dealmaking in the biopharma industry since 2014
-
Access to headline, upfront, milestone and royalty data
-
Access to hundreds of Immunology deal contract documents
-
Comprehensive access to over 850 Immunology deal records
-
The leading Immunology deals by value since 2014
-
Most active Immunology dealmakers since 2014
The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.
In Global Immunology Partnering 2014 to 2021, available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Immunology Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 850 immunology deals.
Analyzing actual contract agreements allows assessment of the following:
-
What are the precise rights granted or optioned?
-
What is actually granted by the agreement to the partner company?
-
What exclusivity is granted?
-
What is the payment structure for…
Read More: Outlook on the Immunology Partnering Market from 2014 to 2021